Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23%

Precipio

25/02/2026 14:44

Overview

Cancer diagnostics firm's preliminary Q4 revenue rises 23% yr/yr to $6.7 mln

Adjusted EBITDA for Q4-2025 reaches $0.95 mln, showing significant improvement

Company reports positive operating cash flow for Q4-2025, excluding unusual items

Outlook

Company to discuss 2026 prospects in shareholder call after 10K filing

Result Drivers

REVENUE GROWTH - Precipio's Q4-2025 revenue increased by 23% year-over-year to $6.7 mln

CASH FLOW POSITIVITY - Positive operating cash flow reported for Q4-2025, excluding unusual items

Company press release: ID:nGNX5kgQyj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$6.70 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)